Kai Pang

Kai Pang

Auto-generated profile, based on publicly available information

Kai Pang

Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Hepatology International
Verified
Journal Article
Closed access
PDF file
QRQuan Rao
Quan Rao
MLMin Li
Min Li
WXWei Xu
Wei Xu
KPKai Pang
Kai Pang
XGXiaoBo Guo
XiaoBo Guo
ZZZhongtao Zhang
Zhongtao Zhang

1 January 2020 in Neoplasma
Verified
Journal Article
Closed access
KPK. Pang
K. Pang
JSJ. Song
J. Song
ZBZ. Bai
Z. Bai
ZZZ. Zhang
Z. Zhang
MiR-15a-5p targets PHLPP2 in gastric cancer cells to modulate platinum resistance and is a suitable serum biomarker for oxaliplatin resistance

1 January 2019 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PDF file
KPKai Pang
Kai Pang
QRQuan Rao
Quan Rao
SQShengqi Qin
Shengqi Qin
LJLan Jin
Lan Jin
HYHongwei Yao
Hongwei Yao
ZZZhongtao Zhang
Zhongtao Zhang
After achieving a clinical complete response through neoadjuvant chemoradiotherapy, a nonoperative management approach for rectal cancer patients known as Wait and Watch (W&W) has gained increasing attention. However, the W&W strategy has been related to higher local recurrence and ambiguous long-term survival. This meta-analysis compared key prognosis indicators between W&W and surgical treatment in an effort to clarify some long-standing points of confusion. Pubmed, Web of Science, EMbase, Cochrane Library were searched for relevant researches comparing W&W with surgery treatment, with a time criteria set from 1 January 2002 to 4 July 2019. Endpoints were 2-year local regrowth/recurrence, 2-year distant metastasis (plus local regrowth/recurrence), 3- and 5-year disease-free survival (DFS), and overall survival (OS). In total, nine studies with 801 patients were enrolled, of which 348 were managed by W&W and 453 by surgery. Surgery patients were further divided into a pathological complete response (pCR) group (all included patients achieved pCR) and a surgery group (consisting of both pCR and non-pCR patients without deliberate screening). Compared with the surgery group, W&W patients have higher 3- and 5-year OS, and are not inferior on 2-year local regrowth (LR), 2-year distant metastasis (DM)/DM+LR, and 3- and 5-year DFS. On the other hand, compared with the pCR group, the W&W group is inferior on 2-year LR, 3- and 5-year DFS, and 5-year OS, and not inferior on 2-year DM/DM+LR and 3-year OS. In contrast with patients undergoing surgical treatment, the W&W group has higher 3- and 5-year OS, and is not inferior on other major prognostic indicators, which, however, is based on the fact that the tumor stage in the W&W group is generally earlier. Versus surgically treated patients who acquired pCR, W&W group is inferior on all major prognostic indicators except 2-year DM/DM+LR and 3-year OS. Additionally, by comparison of cCR definitions across different studies, we conclude that implementation of the strictest cCR criteria is critical for W&W patients to acquire maximum prognostic benefit.

1 August 2020 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
HYHongwei Yao
Hongwei Yao
KPKai Pang
Kai Pang
GXGang Xiao
Gang Xiao
FLFei Li
Fei Li
YXYi Xiao
Yi Xiao
ZZZhongtao Zhang
Zhongtao Zhang

15 March 2021 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
KPKai Pang
Kai Pang
PSPeilin Sun
Peilin Sun
JLJun Li
Jun Li
NZNa Zeng
Na Zeng
XYXiaobao Yang
Xiaobao Yang
ZZZhongtao Zhang
Zhongtao Zhang

12 September 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
KPKai Pang
Kai Pang
YYYun Yang
Yun Yang
DTDan Tian
Dan Tian
NZNa Zeng
Na Zeng
SCShun Cao
Shun Cao
ZZZhongtao Zhang
Zhongtao Zhang
Introduction Recent preclinical studies have discovered unique synergism between radiotherapy and immune checkpoint inhibitors, which has already brought significant survival benefit in lung cancer. In locally advanced rectal cancer (LARC), neoadjuvant radiotherapy plus immune checkpoint inhibitors have also achieved surprisingly high pathological complete response (pCR) rates even in proficient mismatch-repair patients. As existing researches are all phase 2, single-cohort trials, we aim to conduct a randomised, controlled trial to further clarify the efficacy and safety of this novel combination therapy. Methods and analysis Eligible patients with LARC are randomised to three arms (two experiment arms, one control arm). Patients in all arms receive long-course radiotherapy plus concurrent capecitabine as neoadjuvant therapy, as well as radical surgery. Distinguishingly, patients in arm 1 also receive anti-PD-1 (Programmed Death 1) treatment starting at Day 8 of radiation (concurrent plan), and patients in arm 2 receive anti-PD-1 treatment starting 2 weeks after completion of radiation (sequential plan). Tislelizumab (anti-PD-1) is scheduled to be administered at 200 mg each time for three consecutive times, with 3-week intervals. Randomisation is stratified by different participating centres, with a block size of 6. The primary endpoint is pCR rate, and secondary endpoints include neoadjuvant-treatment-related adverse event rate, as well as disease-free and overall survival rates at 2, 3 and 5 years postoperation. Data will be analysed with an intention-to-treat approach. Ethics and dissemination This protocol has been approved by the institutional ethical committee of Beijing Friendship Hospital (the primary centre) with an identifying serial number of 2022-P2-050-01. Before publication to peer-reviewed journals, data of this research will be stored in a specially developed clinical trial database. Trial registration number NCT05245474.